COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - New York Stock Exchange, Inc. - US19247A1007 - Common Stock - Currency: USD
Overall CNS gets a fundamental rating of 6 out of 10. We evaluated CNS against 233 industry peers in the Capital Markets industry. CNS scores excellent on profitability, but there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
In the past year CNS has reported a negative cash flow from operations.
Each year in the past 5 years CNS has been profitable.
In the past 5 years CNS always reported a positive cash flow from operatings.
1.2 Ratios
CNS has a Return On Assets of 18.81%. This is amongst the best in the industry. CNS outperforms 98.28% of its industry peers.
CNS has a Return On Equity of 30.93%. This is amongst the best in the industry. CNS outperforms 95.28% of its industry peers.
The Return On Invested Capital of CNS (20.82%) is better than 97.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CNS is significantly above the industry average of 7.86%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(20.82%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROIC | 20.82% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
CNS's Profit Margin of 29.68% is fine compared to the rest of the industry. CNS outperforms 74.25% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
The Operating Margin of CNS (33.60%) is better than 60.52% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS's Gross Margin of 88.86% is amongst the best of the industry. CNS outperforms 92.27% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
Compared to 1 year ago, CNS has more shares outstanding
The number of shares outstanding for CNS has been increased compared to 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.26 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS's Altman-Z score of 8.26 is amongst the best of the industry. CNS outperforms 91.85% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.26 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.80. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.80, CNS is doing worse than 65.67% of the companies in the same industry.
CNS has a Quick Ratio of 0.80. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.80, CNS is doing worse than 65.24% of the companies in the same industry.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.58% over the past year.
The Earnings Per Share has been growing slightly by 2.50% on average over the past years.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.82%.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.36% yearly.
CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.94% yearly.
EPS Next Y5.14%
EPS Next 2Y9.53%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue Next Year5.95%
Revenue Next 2Y8.21%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.76, CNS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, CNS is valued a bit more expensive than 62.66% of the companies in the same industry.
CNS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 21.84, the valuation of CNS can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CNS is valued a bit more expensive than the industry average as 60.09% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, CNS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.76 | ||
| Fwd PE | 21.84 |
4.2 Price Multiples
72.10% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)5.02
PEG (5Y)10.31
EPS Next 2Y9.53%
EPS Next 3Y10.74%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.20%, CNS has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 7.77, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is a higher than the S&P500 average which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.2% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
77.43% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP77.43%
EPS Next 2Y9.53%
EPS Next 3Y10.74%
76.77
-0.81 (-1.04%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners59.52%
Inst Owner Change0%
Ins Owners22.52%
Ins Owner Change0.57%
Market Cap3.91B
Analysts48
Price Target87.72 (14.26%)
Short Float %6.68%
Short Ratio10.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.2% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP77.43%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.32%
Min EPS beat(2)-2.29%
Max EPS beat(2)-0.35%
EPS beat(4)1
Avg EPS beat(4)-1.1%
Min EPS beat(4)-2.29%
Max EPS beat(4)0.49%
EPS beat(8)2
Avg EPS beat(8)-0.99%
EPS beat(12)6
Avg EPS beat(12)0.97%
EPS beat(16)10
Avg EPS beat(16)3.04%
Revenue beat(2)1
Avg Revenue beat(2)-4.71%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.78%
PT rev (3m)-7.03%
EPS NQ rev (1m)-0.66%
EPS NQ rev (3m)-6.79%
EPS NY rev (1m)0.66%
EPS NY rev (3m)-7.85%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)2.4%
Revenue NY rev (1m)0.9%
Revenue NY rev (3m)1.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.76 | ||
| Fwd PE | 21.84 | ||
| P/S | 7.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.71 | ||
| P/tB | 8.01 | ||
| EV/EBITDA | 20.35 |
EPS(TTM)2.98
EY3.88%
EPS(NY)3.51
Fwd EY4.58%
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS10.38
BVpS9.96
TBVpS9.58
PEG (NY)5.02
PEG (5Y)10.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROCE | 27.12% | ||
| ROIC | 20.82% | ||
| ROICexc | 23.12% | ||
| ROICexgc | 25.32% | ||
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexcg growth 3Y-36.94%
ROICexcg growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 74.13% | ||
| Cap/Sales | 1.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 8.26 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
EPS Next Y5.14%
EPS Next 2Y9.53%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
Revenue Next Year5.95%
Revenue Next 2Y8.21%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
EBIT growth 1Y11.24%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year16.8%
EBIT Next 3Y17.3%
EBIT Next 5Y16.09%
FCF growth 1Y-117.6%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-111.18%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%